ADVERTISEMENT
Regeneron Pharmaceuticals Inc. announced today that Eylea was approved for the treatment of patients with neovascular, or wet, age-related macular degeneration (AMD) in Japan by the Japanese Ministry of Health, Labour and Welfare.
The announcement comes just a week after a key European commission recommended Eylea, which in November 2011 was approved by the Food and Drug Administration for the treatment of wet AMD in the U.S., for approval for the treatment of the disease in the European Union.
